Noninvasix

Noninvasix will become the first company to non-invasively monitor the severity of sepsis and septic shock, enabling clinicians to diagnose and monitor the response to treatment for tissue hypoxia in real time. Its patented photoacoustic platform technology is the first solution for non-invasive, continuous measurement of central venous saturation. Integrating Noninvasix into ICU workflows allows clinicians to diagnose critically ill patients more quickly and accurately, as well as tailor treatments to improve outcomes. Future developments, enhancements, and evidence will expand the use and clinical impact of this technology to other indications and settings.